Suraksha Diagnostic Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suraksha Diagnostic Limited submitted its unaudited financial results for the quarter ended June 30, 2025, approved by the Board on August 8, 2025. On a standalone basis, revenue from operations rose about 16% YoY to ₹7,027.90 lakhs from ₹6,043.29 lakhs, while profit after tax grew around 18% YoY to ₹984.87 lakhs (from ₹833.05 lakhs). Standalone EPS stood at ₹1.89 versus ₹1.56 a year earlier. On a consolidated basis, including the newly acquired subsidiary Fetomat Wellness, revenue was ₹7,258.63 lakhs and PAT was ₹917.51 lakhs. The statutory auditor, MSKA & Associates, issued an unmodified limited review conclusion on both sets of results.
A steady quarter showing healthy double-digit growth in both revenue and profits, supported by the recent Fetomat acquisition now contributing to consolidated numbers. However, standalone EBITDA margin dipped slightly YoY (roughly 35% to 34%), which investors should watch for cost pressure, even as headline numbers remain positive.